IP Library Granted Patent US 9,193,697
Granted Patent B2
US 9,193,697 · App. 13/635,303 · Granted Nov 24, 2015

Oxazole derivatives useful as modulators of FAAH

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,193,697
App. No.
13/635,303
Granted
Nov 24, 2015
Kind
B2
Abstract

The present invention is directed to certain Oxazole derivatives which are useful as modulators of Fatty Acid Amide Hydrolase (FAAH) and as FAAH imaging agents. The invention is also concerned with pharmaceutical formulations comprising these compounds as active ingredients and the use of the compounds and their formulations in the treatment of certain disorders, including osteoarthritis, rheumatoid arthritis, diabetic neuropathy, postherpetic neuralgia, skeletomuscular pain, and fibromyalgia, as well as acute pain, migraine, sleep disorder, Alzheimer Disease, and Parkinson's Disease.

Claims (61)

1. A compound of the Formula

wherein:

n is 0, 1 or 2, and

R 1 is selected from the group consisting of:

(1) phenyl, and

(2) pyridyl,

optionally mono or di-substituted with substituents R 4 and R 5 , which are independently selected from the group consisting of

(a) mono, di or tri-halo C 1-4 alkyl,

(b) —C 1-4 alkyl optionally substituted with one or two substituents selected from hydroxyl, —CHF 2 and —CF 3 ,

(c) —S(O) n C 1-4 alkyl,

(d) —C(O)—NR 10 R 11 ,

wherein R 10 and R 11 are each independently selected from H and C 1-4 alkyl,

(e) HET 2 ,

wherein HET 2 is a 5 to 10-membered aromatic, partially aromatic or non-aromatic mono- or bicyclic ring, or N-oxide thereof, said containing 1 to 4 heteroatoms selected from O, S and N, and optionally mono or di-substituted with substituents selected from:

(1) halo,

(2) —OH,

(3) —C 1-4 alkyl optionally substituted with hydroxy, halo or cyano,

(4) —CF 3 ,

(5) —OC 1-4 alkyl optionally substituted with hydroxyl or halo, and

(6) —C(O)O—C 1-3 alkyl; and

R 3 is selected from the group consisting of:

(1) phenyl, and

(3) pyridyl, wherein R 3 is optionally mono or di-substituted with halo, haloC 1-4 alkyl,

or —OC 1-4 alkyl optionally substituted with halo.

2. A compound selected from the group consisting of

No.

Structure

1

2

4

5

6

7

8

9

10

or a pharmaceutically acceptable salt thereof.

3. A compound selected from the group consisting of

No.

Structure

B5.1 1

B5.3 3

 9

14

16

17

18

19

20

21

22

24

26

27

28

29

30

31

32

or a pharmaceutically acceptable salt thereof.

4. A pharmaceutical composition which comprises an inert carrier and a compound of claim 1 or a pharmaceutically acceptable salt thereof.

Assignments (2)
MERGER Recorded Aug 8, 2022
From: MERCK SHARP & DOHME CORP.
To: MERCK SHARP & DOHME LLC
Reel/Frame 061102/0145 →
CORRECTIVE ASSIGNMENT TO CORRECT THE ASSIGNORS TO INCLUDE EVAN FOSTER SHALEN PREVIOUSLY RECORDED ON REEL 030116 FRAME 0430. ASSIGNOR(S) HEREBY CONFIRMS THE MISSING ASSIGNOR IS EVAN FOSTER SHALEN WHO WAS PREVIOUSLY MISTAKENLY OMITTED FROM THE ASSIGNMENT RECORDATION FORM.. Recorded Aug 29, 2013
From: YANG, ZHIQIANG; NANTERMET, PHILIPPE G.; KREATSOULAS, CONSTANTINE; MOORE, KEITH P.; SHALEN, EVAN FOSTER
To: MERCK SHARP & DOHME CORP.
Reel/Frame 031123/0840 →